$FULC News

Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines

Fulcrum Therapeutics And Slate Medicines Merge In All-Stock Deal; Combined Company To Operate As Slate Medicines

A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring

Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

UPDATED: Fulcrum Therapeutics Launches Restructuring Plan Following Discontinuation Of Pociredir For Sickle Cell Disease, Cutting Workforce By 85% From 57 To 9 Employees And Recording ~$4.2M In Restructuring Charges

What's Going On With Fulcrum Therapeutics Stock On Thursday?

Fulcrum: 'Hold' On Pociredir Discontinuation And Strategic Alternatives Shift

FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End

JP Morgan Downgrades Fulcrum Therapeutics to Underweight

This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3

Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4

HC Wainwright & Co. Downgrades Fulcrum Therapeutics to Neutral, Lowers Price Target to $3

FULC Stock Crashes After Hours: What Investors Need To Know

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk

Fulcrum Therapeutics Discontinues Sickle Cell Disease Program After US FDA Raises Malignancy Concerns

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review